Overview of Atropina

Property	Description
Active ingredient	Atropine Sulfate
Form	Injection Solution, Ophthalmic Solution, Tablets
Pharmacological class	Anticholinergic Agent / Muscarinic Receptor Antagonist
Common use	Modulation of heart rate and glandular secretions
Origin	Naturally derived Tropane alkaloid (now often synthesized)

Atropine Sulfate: Definition and Pharmacological Classification

Atropina is the name used for a medication containing the active component Atropine Sulfate, which acts as a powerful agent for modulating the involuntary functions of the body. It is formally classified as an Anticholinergic agent and, more specifically, as a competitive Muscarinic receptor antagonist. This pharmacological classification defines the drug's fundamental ability to interrupt nerve signals that control vital processes such as heart rate and gut mobility.

The chemical entity is recognized globally as an Essential Medicine on the WHO Model List due to its critical role in managing specific acute and emergency medical situations. Its status as a widely available generic formulation ensures its accessibility in acute care settings worldwide.

Origin, Composition, and Available Forms of Atropina

Atropina's active compound, atropine, is classified as a Tropane alkaloid that was historically isolated from plants of the Solanaceae family, although it is now most frequently supplied as a purified, often synthesized sulfate salt. The medication is a single-ingredient product available primarily as a sterile Injection solution for rapid parenteral delivery, and as a sterile Ophthalmic solution (eye drops) for targeted local action.

Its versatility is confirmed by clinical recognition for two distinct applications: the injectable form is favored in acute scenarios such as anesthesia to manage bodily functions, while the ophthalmic form is specifically formulated for precise local effects in the eye. Clinical use confirms that Atropine is effective at dilating the pupil (mydriasis) for diagnostic purposes.

General Purpose of Anticholinergic Agents like Atropine

The general purpose of Atropine Sulfate is to function as a crucial internal regulatory tool by immediately neutralizing specific parasympathetic nerve activity. By performing its fundamental parasympatholytic function, the medicine is indispensable for managing severe physiological events such as counteracting dangerously slow heart rhythms (bradycardia), relieving acute and severe internal smooth muscle spasms, and significantly reducing excessive secretions in situations requiring airway control.

Regulatory References

What side effects are possible with Atropina?

Possible Side Effects and Safety Information

The official safety profile for Atropine Sulfate is categorized by the specific system-organ classes affected, reflecting its potent activity as an anticholinergic agent. Adverse reactions commonly stem from the inhibition of parasympathetic signaling.

Official Adverse Reaction Scope

Side effects are officially classified by frequency. Very common adverse reactions documented in regulatory sources include photophobia (sensitivity to light). Common effects include blurred vision, dry mouth, eye pain, and an increased heart rate, or tachycardia. Effects for which the frequency cannot be reliably estimated, often reported post-marketing, include serious reactions such as anaphylaxis and mental confusion.

System-Organ Class	Key Adverse Reactions (as documented)
Eye Disorders	Blurred vision, photophobia, raised intraocular pressure, decreased lacrimation.
Cardiac Disorders	Tachycardia, palpitations, and various arrhythmias.
Gastrointestinal Disorders	Dryness of the mouth and throat, constipation, nausea, and vomiting.
Nervous/Psychiatric Disorders	Drowsiness, delirium, irritability, and mental confusion.

Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several serious adverse reactions, including the potential for anaphylaxis and the precipitation of acute closed-angle glaucoma. Risks also include the worsening of existing Ischemic Heart Disease due to drug-induced tachycardia, and the potential for complete urinary retention.

Safety constraints noted in regulatory labels indicate that the medicine is contraindicated in individuals with known hypersensitivity to the drug or in those with closed-angle glaucoma. Additionally, caution is advised for patients, particularly children, in high ambient temperatures due to the potential for hyperthermia resulting from inhibited sweating.

Population-Specific Notes

The label includes specific safety notes for certain populations. Older adults may be more susceptible to central nervous system effects, such as dizziness and confusional states, and to urinary difficulty. Similarly, caution is required when administering to children with certain neurological conditions, such as Down Syndrome, due to increased susceptibility to systemic toxicity.

Overdose and Emergency Response

The official regulatory documents define the overdose of Atropina (Atropine Sulfate) primarily through severe anticholinergic toxicity. Documented clinical manifestations of overdosage include delirium, hallucinations, marked excitement, and significant cardiovascular effects such as tachycardia and palpitations. Systemic signs also feature elevated body temperature (fever), dilated pupils, and hot dry skin. Overdosage is associated with severe outcomes that can be life-threatening, requiring immediate intervention for respiratory failure—the usual cause of death—and circulatory collapse.

Immediate medical attention must be sought for toxic overdosage. The documented treatment strategy focuses on supportive care and the administration of Physostigmine, which is specified as the specific antidote that rapidly abolishes the severe Central Nervous System effects, including delirium and coma. Supportive procedures involve providing respiratory assistance and administering a short-acting barbiturate or diazepam to control marked excitement and convulsions. Cooling measures are also listed to manage hyperthermia. Regulatory documents emphasize that pediatric populations are more susceptible to toxic effects, noting that 10 mg or less may potentially be fatal in children.

Therapeutic Uses of Atropina

What Atropina Treats: Main Uses and Benefits

The medication is applied in managing symptoms related to heightened physiological activity in acute and specialized settings. It is generally used to help address symptom clusters that may become intense or disruptive. This includes managing critically slow heart rhythms (symptomatic bradycardia), addressing the systemic crisis caused by organophosphate or nerve agent poisoning, and treating specific inflammatory conditions in the eye like uveitis and iritis.

In critical care, the supportive benefit is that it assists with maintaining stability and provides support that helps with elevating the heart rate when it poses a risk to circulation. When applied in toxicological contexts, it is relevant for managing symptom clusters related to excessive bronchial and glandular secretions, which contributes to easing the overall symptom load and helps support respiratory function.

“It is commonly used when short-term symptomatic assistance is needed to stabilize critical physiological functions.”

For ophthalmic use, which often involves pediatric patients, the medication helps ease physical discomfort and supports therapeutic efforts that may improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Severe Bradycardia and Excessive Secretions

Regulatory References

FDA DailyMed label for Atropine Sulfate Injection

Eligibility and Restrictions for Use

Eligibility for Atropine Sulfate

Official regulatory documents classify patient eligibility for Atropine Sulfate by defining groups for whom use is permitted, restricted, or strictly prohibited (contraindicated).

Contraindications (Must Not Use): Use is strictly prohibited for patients with a known hypersensitivity to the drug or excipients, closed-angle glaucoma, or conditions involving obstruction of the gastrointestinal or urinary tract, such as pyloric stenosis, paralytic ileus, or bladder neck obstruction. It is also contraindicated in patients with severe ulcerative colitis.

Restricted Use (Use with Caution): Caution is mandated for older adults due to increased susceptibility to central nervous system effects. Restricted use is also specified for patients with Ischemic Heart Disease, tachyarrhythmias, severe renal or hepatic impairment, and certain pulmonary conditions like chronic lung disease.

Age and Physiological States: Atropine is generally permitted for adults and children, but the ophthalmic solution is not recommended for infants under three months of age. Use during pregnancy and lactation is only permitted if deemed clearly needed or essential, as the drug crosses the placenta and appears in breast milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Atropine Sulfate primarily through pharmacodynamic synergy and the physical alteration of co-administered drug absorption.

Pharmacodynamic and Absorption Interactions

Interaction Domain	Interacting Agents / Description	Official Outcome
Anticholinergic Synergy	Co-administration with other anticholinergic agents (e.g., tricyclic antidepressants, amantadine).	Enhancement of atropine’s effects (increased risk of antimuscarinic toxicity).
Systemic Risk	Monoamine Oxidase Inhibitors (MAOIs).	Combination generally not recommended due to potential for hypertensive crisis.
Altered Absorption	Oral medicines like Mexiletine and Ketoconazole; Sublingual preparations (e.g., Nitrates).	Reduced gastrointestinal motility decreases the absorption rate of oral drugs; reduced dissolution reduces effectiveness of sublingual preparations.

Administration Constraints

Interaction Type	Interacting Agent	Official Requirement
Mandatory Sequence	Neostigmine.	Atropine must be administered before Neostigmine when used for reversal of non-depolarizing muscle relaxants.

No interactions involving Cytochrome P450 enzymes or specific drug transporters (P-gp, OATP, BCRP) are explicitly documented in official regulatory prescribing information. The profile lists no specific interactions with food, alcohol, or herbal products.

Mechanism of Action

How Atropina Works: Mechanism of Action

Blocking Muscarinic Receptors to Neutralize Cholinergic Signals

Atropina is a competitive antagonist that acts on all five subtypes of Muscarinic Acetylcholine Receptors (M1-M5), particularly those found on the smooth muscle and glands of the parasympathetic nervous system. By binding to and blocking these receptors, it prevents the neurotransmitter acetylcholine (ACh) from activating cellular responses, thereby inhibiting the signaling of the parasympathetic system, which controls rest and digestion functions.

Shifting Autonomic Balance and Increasing Heart Rate

The blockade of M2 receptors in the heart (SA and AV nodes) removes the constant inhibitory signal, or vagal tone, exerted by the parasympathetic system. This functional inhibition allows the sympathetic nervous system's influence to become dominant, causing an increase in heart rate (tachycardia) and enhanced electrical conduction velocity through the atria.

Inhibiting Secretion and Relaxing Smooth Muscle

The drug blocks M3 receptors in exocrine glands and smooth muscle cells, influencing exocrine secretion and visceral motility pathways. This action results in a reduced rate of secretion from exocrine glands (salivary, sweat, bronchial) and causes the relaxation of smooth muscle in the airways (bronchodilation), gastrointestinal tract (decreased peristalsis), and eyes (mydriasis and cycloplegia). This establishes the physiological consequences of reduced secretion and smooth muscle relaxation.

Dosage and Administration Information

The administration of Atropina is governed by detailed instructions that distinguish between acute systemic use via injection and scheduled local use via ophthalmic solution.

Systemic Administration (Injection)

The injectable form is delivered via Intravenous (IV), Intramuscular (IM), or Subcutaneous (SC) routes, with Intraosseous (IO) and Endotracheal (ET) routes reserved for emergency protocols. For managing symptomatic bradycardia, the usual adult starting dose is 0.5 mg to 1 mg IV, which may be repeated every 3 to 5 minutes, generally not exceeding a 3 mg total dose. As an antidote for poisoning, the initial systemic dose is higher, often 2 mg to 3 mg, repeated every 5 to 30 minutes, with administration titrated until specific physiological changes are observed. For pediatric patients requiring injection, the dose is calculated based on body weight, commonly 0.02 mg/kg. Preparation for injection involves visually inspecting the solution for clarity, and for ET delivery, the drug must be diluted in sterile water or normal saline.

Topical Administration (Ophthalmic)

The Ophthalmic Solution is applied topically as one drop to the eye, forty minutes prior to the intended maximal dilation time. For individuals 3 years of age or older, this application may be repeated up to twice daily as needed. A specific procedural instruction for topical administration is to apply pressure to the lacrimal sac immediately following the drop to limit systemic absorption. Usage guidelines advise restricting the dose to no more than one drop per day for children between 3 months and 3 years.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Atropina

This section describes the research that has been conducted on Atropina (Atropine), explaining the types of studies available and what they monitored, without offering any medical advice or interpretation of the findings. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.

Evidence for Use in Organophosphate or Carbamate Poisoning

Atropina was studied for its use in situations of organophosphate or carbamate poisoning. The research examined outcomes related to acute survival and physiological change. Studies monitored the patient's immediate physiological response. Comparative evidence is lacking against an inactive treatment due to the urgent nature of the condition, and follow-up durations were limited to the acute hospital stay.

Evidence for Use in Symptomatic Bradycardia (Slow Heart Rate)

Atropina was studied for use in cases of symptomatic bradycardia, a condition where the heart beats unusually slowly. The evidence primarily comes from observational studies and clinical practice guidance, where outcomes describing episodic or acute changes were evaluated in adult populations. Studies monitored outcomes such as the acute increase in heart rate and changes related to physiological strain. Evidence is limited, lacking recent, large-scale randomized trials in all specific scenarios.

Evidence for Ophthalmic Uses: Pupil Dilation and Accommodation

Atropina was studied for ophthalmic uses, and research examined outcomes related to pupil dilation (mydriasis) and paralysis of the eye's focusing muscle (cycloplegia). Studies monitored the time it took for these effects to begin and return to normal. Follow-up durations were limited to the acute phase necessary to monitor the drug's onset and offset kinetics.

Evidence for Use in Pediatric Myopia Progression (Topical)

Topical low-concentration Atropina was evaluated in numerous Randomized Controlled Trials (RCTs) and long-term observational follow-up studies. Research examined outcomes related to changes in the length of the eyeball (axial length) and refraction measurements over several years. Results apply only to the populations studied, which was observed to be primarily of Asian descent, and long-term effects on axial length and refraction years after treatment ends are not fully established.

Frequently Asked Questions (FAQ)

Common questions about Atropina (FAQ)

Q: Is Atropina the same thing as belladonna extract?

Atropine is the purified, active chemical component that was historically isolated from the Belladonna plant (Atropa belladonna) and other related plants. While both are related, Atropina (Atropine Sulfate) is a specific, standardized chemical compound used as a medicine. Belladonna extract, conversely, contains a less predictable mixture of various substances.

Q: How quickly does Atropina start working in an emergency setting?

Regulatory documents do not provide a specific time-to-onset for the injectable solution used in emergencies. For its topical use as an eye drop, however, official product information indicates that the maximal pupil dilation effect is generally achieved approximately 40 minutes after application.

Q: What are the most common reasons a doctor prescribes Atropina?

Official indications confirm Atropina's use for managing conditions such as symptomatic slow heart rate (bradycardia) and as an antidote for certain types of poisoning. It is also commonly indicated as an eye drop to temporarily dilate the pupil for examination or to manage specific eye conditions.

Q: Can Atropina cause temporary blurry vision even when not used for the eyes?

Yes, blurred vision is listed as a potential adverse reaction following systemic (non-eye drop) administration. This is because the drug works by affecting signals throughout the body, which can include the muscles that control the eye's ability to focus.

Q: How long does the effect of Atropina typically last?

The duration of Atropina's effects varies significantly based on how it is administered. For the ophthalmic solution, official labeling indicates that the effects on the eyes (pupil dilation and focusing changes) may last for up to 14 days after discontinuation.

Q: Can taking Atropina make you feel anxious or restless?

Official drug labels list several central nervous system (CNS) effects as possible adverse reactions. These include symptoms such as irritability, restlessness, delirium, and mental confusion, which may be related to feelings of anxiety.

Q: Are there any common over-the-counter supplements that interact with Atropina?

Official drug labels warn that Atropina interacts with any medication or supplement that possesses anticholinergic activity, as this combination can enhance side effects. Official drug information suggests that healthcare providers should be informed of all medications, including vitamins and herbal products, to review potential risks.

Q: Does Atropina help with severe sweating?

Atropina's action inhibits secretions, including those from sweat glands, which is why a potential side effect is the inability to sweat (anhidrosis). However, regulatory evidence does not indicate its use as a designated treatment for severe localized sweating (hyperhidrosis).

Q: Why would someone need Atropina for nerve agent poisoning?

Atropina is indicated as an antidote for poisoning by certain susceptible organophosphorus nerve agents or insecticides. It is used because it blocks specific receptors, which helps to counteract dangerous effects of the poisoning, such as excessive secretions and breathing difficulties.

Q: Is Atropina available in pill form or only injections and drops?

The medicine is primarily available as a sterile injection solution for rapid use and as a sterile ophthalmic solution (eye drops) for localized action. It is also available in oral tablet form when combined with other active ingredients to address specific conditions.

Q: Can Atropina affect how much you urinate?

Atropina’s anticholinergic action can impact bladder function. Official safety information notes that while it may cause a decreased frequency of urination, complete urinary retention (inability to pass urine) is also a potential concern.

Q: Is Atropina addictive or habit-forming?

Atropine itself is not typically considered habit-forming. However, when it is included in certain combination products with other controlled substances, that combination product may carry a risk of dependence due to the other component.

Q: Can Atropina be used to treat muscle spasms?

Atropina is pharmacologically classified as an antispasmodic because it relaxes smooth muscle tissue, particularly in the gastrointestinal and urinary tracts. It is sometimes used as a treatment alongside other therapies for conditions involving acute spasms in these areas.

Q: What research exists about Atropina's role in reversing certain toxins?

Official regulatory research confirms Atropina's critical role as an antidote. Studies have investigated its effectiveness in reversing the toxic effects of organophosphate and carbamate poisoning.

Q: How does the mechanism of Atropina compare to that of pilocarpine?

Atropina acts as a receptor antagonist, which means it works by blocking specific nerve signals in the body. Pilocarpine, which acts as an agonist, has effects on the body that are generally the opposite of Atropina’s receptor-blocking action.

Q: Is it normal to feel flushed or warm after taking Atropina?

Yes, official safety documents list flushing and a feeling of warmth as documented adverse reactions. This can occur because the medication may inhibit sweating, making it harder for the body to regulate its temperature.

Q: Does Atropina interact with common cold or allergy medicines?

Atropina is known to interact with other medicines that have anticholinergic activity, a property found in many common cold, allergy, or sleep-aid preparations. Combining these drugs may increase the risk of anticholinergic side effects.

Q: Is there any evidence for Atropina use in managing drooling?

Due to its mechanism of reducing saliva secretion, the use of Atropina for managing excessive drooling (sialorrhea) has been explored in various studies. Its suitability for this purpose should be discussed with a healthcare provider.

Q: Is Atropina only used in emergency situations, or for chronic conditions too?

While it is a key agent in acute, life-saving emergencies (like severe slow heart rate), it is also used for chronic conditions. Examples include the long-term topical use of low-concentration drops for managing myopia (nearsightedness) progression in children.

Q: How do emergency personnel decide on the correct Atropina dose in a crisis?

In critical situations, such as poisoning, the dose is managed via titration. This means the dose is carefully monitored and adjusted by medical professionals until target physiological changes are achieved, such as a decrease in secretions.

Q: What are the signs of an allergic reaction to Atropina?

Official safety profiles highlight the risk of serious allergic reactions, including anaphylaxis. Other reported allergic manifestations include hives, itching, skin rash, or the development of red bumps on the skin.

Q: What does official information say about using Atropina during pregnancy?

Official regulatory documents indicate that there are no adequate and well-controlled studies in pregnant women. The medicine should only be used during pregnancy if the expected benefit is considered to outweigh the potential risk to the developing fetus.

Q: Can children 2 years old use Atropina for eye treatment?

For ophthalmic solutions (eye drops), official product labeling includes specific age restrictions and instructions for children between 3 months and 3 years to limit the potential for the drug's absorption into the body. Specific instructions must be followed as directed by a healthcare professional.

Q: Does Atropina interact with common antidepressants like SSRIs?

Official drug labels specifically warn about interactions with other medications that have anticholinergic activity, such as tricyclic antidepressants. Combining Atropina with any agent possessing anticholinergic properties can increase the risk of side effects.

Q: Can Atropina cause difficulty with heat regulation?

Yes, regulatory documents caution that Atropina can cause a rise in body temperature (hyperpyrexia). This is because the medication inhibits the body's natural sweating process, making it harder for the body to cool itself down in warm environments.

Q: Is Atropina found in any natural sources?

The active compound in the medicine is a Tropane alkaloid that was historically isolated from natural sources. It primarily comes from the deadly nightshade (Atropa belladonna) and other plants belonging to the Solanaceae family.

Q: How is Atropina generally administered by paramedics in an ambulance?

Atropina can be administered through various routes, including intravenous (IV) or intramuscular (IM) injection. In field emergency settings, it is commonly delivered via intramuscular (IM) injection, often utilizing an auto-injector for rapid use.

How should Atropina be stored and disposed of?

How to Store and Dispose of Atropine Sulfate

Storage Requirements

Atropine Sulfate Injection must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F). Temperatures may briefly deviate between 15°C and 30°C. It is required that the product not be frozen.

Specific formulations, such as ophthalmic solutions, must be protected from light and stored in a tightly closed container. The medicine must, without exception, be kept out of the sight and reach of children.

Stability and Disposal

To ensure quality, the injection must be visually inspected before use and must not be used if the solution is discolored or contains particulate matter. For single-dose injections, any unused portion must be discarded after administration. Certain eye drops must be discarded 4 weeks after opening.

All expired or unused product must be disposed of in accordance with local requirements. Regulatory guidelines state that the medicine must not be disposed of via wastewater or general household waste.

Atropina